G protein‐coupled receptor 84 controls osteoclastogenesis through inhibition of NF‐κB and MAPK signaling pathways

GPR84, a member of the G protein‐coupled receptor family, is found predominantly in immune cells, such as macrophages, and functions as a pivotal modulator of inflammatory responses. In this study, we investigated the role of GPR84 in receptor activator of nuclear factor‐κB ligand (RANKL)‐induced osteoclast differentiation. Our microarray data showed that GPR84 was significantly downregulated in osteoclasts compared to in their precursors, macrophages. The overexpression of GPR84 in bone marrow‐derived macrophages suppressed the formation of multinucleated osteoclasts without affecting precursor proliferation. In addition, GPR84 overexpression attenuated the induction of c‐Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), which are transcription factors that are critical for osteoclastogenesis. Furthermore, knockdown of GPR84 using a small hairpin RNA promoted RANKL‐mediated osteoclast differentiation and gene expression of osteoclastogenic markers. Mechanistically, GPR84 overexpression blocked RANKL‐stimulated phosphorylation of IκBα and three MAPKs, JNK, ERK, and p38. GPR84 also suppressed NF‐κB transcriptional activity mediated by RANKL. Conversely, GPR84 knockdown enhanced RANKL‐induced activation of IκBα and the three MAPKs. Collectively, our results revealed that GPR84 functions as a negative regulator of osteoclastogenesis, suggesting that it may be a potential therapeutic target for osteoclast‐mediated bone‐destructive diseases.

[1]  Seung Hun Lee,et al.  Free Fatty Acid Receptor 4 (GPR120) Stimulates Bone Formation and Suppresses Bone Resorption in the Presence of Elevated n-3 Fatty Acid Levels. , 2016, Endocrinology.

[2]  Shin-Yoon Kim,et al.  G Protein‐Coupled Receptor 120 Signaling Negatively Regulates Osteoclast Differentiation, Survival, and Function , 2016, Journal of cellular physiology.

[3]  M. Tremblay,et al.  GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer’s disease , 2015, Brain, Behavior, and Immunity.

[4]  Mathew W. Wright,et al.  International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein–Coupled Receptors , 2015, Pharmacological Reviews.

[5]  Jianlong Wang,et al.  GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis. , 2014, Blood.

[6]  T. Oda,et al.  Medium-chain Fatty Acid-sensing Receptor, GPR84, Is a Proinflammatory Receptor , 2013, The Journal of Biological Chemistry.

[7]  T. Alquier,et al.  The Free Fatty Acid Receptor G Protein-coupled Receptor 40 (GPR40) Protects from Bone Loss through Inhibition of Osteoclast Differentiation* , 2013, The Journal of Biological Chemistry.

[8]  D. Oh,et al.  The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity , 2011, Current opinion in clinical nutrition and metabolic care.

[9]  S. Watkins,et al.  GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects , 2010, Cell.

[10]  K. Mackie,et al.  The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo , 2009, Proceedings of the National Academy of Sciences.

[11]  Jian Luo,et al.  Regulation of bone formation and remodeling by G-protein-coupled receptor 48 , 2009, Development.

[12]  A. Su,et al.  Expression analysis of G Protein-Coupled Receptors in mouse macrophages , 2008, Immunome research.

[13]  H. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[14]  S. Teitelbaum,et al.  The osteoclast: friend or foe? , 2008, Annual review of pathology.

[15]  E. Wagner,et al.  NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1* , 2007, Journal of Biological Chemistry.

[16]  C. Bouchard,et al.  G protein‐coupled receptor 84, a microglia‐associated protein expressed in neuroinflammatory conditions , 2007, Glia.

[17]  S. Teitelbaum Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.

[18]  Hiroshi Takayanagi,et al.  The molecular understanding of osteoclast differentiation. , 2007, Bone.

[19]  H. Tian,et al.  Medium-chain Fatty Acids as Ligands for Orphan G Protein-coupled Receptor GPR84* , 2006, Journal of Biological Chemistry.

[20]  Y. Kadono,et al.  Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.

[21]  W. Richards,et al.  The G-Protein-Coupled Receptor GPR103 Regulates Bone Formation , 2006, Molecular and Cellular Biology.

[22]  C. Venkataraman,et al.  The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 crosslinking. , 2005, Immunology letters.

[23]  H. Aburatani,et al.  Nuclear Factor of Activated T-cells (NFAT) Rescues Osteoclastogenesis in Precursors Lacking c-Fos* , 2004, Journal of Biological Chemistry.

[24]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[25]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[26]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[27]  S. Yousefi,et al.  Cloning and expression analysis of a novel G‐protein‐coupled receptor selectively expressed on granulocytes , 2001, Journal of leukocyte biology.

[28]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[29]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Ulrich Siebenlist,et al.  Requirement for NF-κB in osteoclast and B-cell development , 1997 .

[31]  E. Wagner,et al.  Bone and haematopoietic defects in mice lacking c-fos , 1992, Nature.

[32]  B. Spiegelman,et al.  Pleiotropic effects of a null mutation in the c-fos proto-oncogene , 1992, Cell.

[33]  J. Caamaño,et al.  Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. , 1997, Nature medicine.

[34]  A. Leonardi,et al.  Requirement for NF-kappaB in osteoclast and B-cell development. , 1997, Genes & development.